E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Amyotrophic Lateral Sclerosis (ALS) |
Esclerosis Lateral Amiotrófica (ELA) |
|
E.1.1.1 | Medical condition in easily understood language |
Lou Gehrig's disease |
Enfermedad de Lou Gehrig |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10077024 |
E.1.2 | Term | Familial amyotrophic lateral sclerosis |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10002026 |
E.1.2 | Term | Amyotrophic lateral sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10052653 |
E.1.2 | Term | Amyotrophic lateral sclerosis gene carrier |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the efficacy of BIIB067 when initiated in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). |
El objetivo principal de este estudio es evaluar la eficacia de BIIB067 cuando se inicia en portadores adultos presintomáticos de una mutación de superóxido dismutasa 1 (SOD1) con neurofilamento (NF) elevado. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study are to evaluate the safety and tolerability of BIIB067 and to evaluate the effect of BIIB067 on pharmacodynamics (PD)/treatment response biomarkers. |
Los objetivos secundarios de este estudio son evaluar la seguridad y tolerabilidad de BIIB067 y evaluar el efecto de BIIB067 sobre los biomarcadores de farmacodinámica (PD) / respuesta al tratamiento. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Key Part A Inclusion Criteria: - Participants should have a protocol-defined rapidly progressive SOD1 mutation, confirmed by a central reader, or a SOD1 mutation that is adjudicated for inclusion by an external mutation adjudication committee. - Participants with plasma NfL level less than the protocol-defined threshold. - Participants who are clinically presymptomatic for ALS (i.e., must not have clinically manifested ALS). |
Criterios clave de inclusión de la Parte A: - Los participantes deben tener una mutación SOD1 de progresión rápida definida por el protocolo, confirmada por un lector central, o una mutación SOD1 adjudicada para su inclusión por un comité externo de adjudicación de mutaciones. - Participantes con niveles plasmáticos de NfL menor que el umbral definido por el protocolo. - Participantes clínicamente presintomáticos de ELA (es decir, no deben tener ELA clínicamente manifestada). |
|
E.4 | Principal exclusion criteria |
Key Part A Exclusion Criteria: - History or positive test result at screening for human immunodeficiency virus (HIV). The requirement for testing at Screening may be omitted if it is not permitted by local regulations. - Current hepatitis C infection (defined as positive Hepatitis C Virus (HCV) antibody and detectable HCV RNA). Participants with positive HCV antibody and undetectable HCV Ribonucleic Acid (RNA) are eligible to participate in the study (United States Centers for Disease Control and Prevention). - Current hepatitis B infection (defined as positive for hepatitis B surface antigen (HBsAg) and/or anti-Hepatitis B Core antibody (HBc)). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-hepatitis B surface antibody (HBs) or vaccination (defined asnegative HBsAg, negative anti-HBc, and positive anti- HBs) are eligible to participate in the study. - History of systemic hypersensitivity reaction to tofersen, the excipients contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study. - History of confounding neuromuscular or neurological disorder that is expected to have a progressive (i.e., worsening) course during the study, and/or is expected to be associated with elevations in NF, in the opinion of the Investigator. - Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that if not managed optimally could place a participant at an increased risk for intraoperative or postoperative bleeding. - Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression ≤ 90 days of Screening, which in the opinion of the Investigator would interfere with the study procedures. - Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication (e.g., clopidogrel) that cannot be safely continued or held for an LP procedure, if necessary, according to local or institutional guidelines and/or Investigator determination. - Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed. - Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment, biological agent, device, or approved therapy for investigational use. Participation in a noninterventional study focused on ALS natural history may be allowed at the discretion of the Investigator.
NOTE: Other protocol defined Inclusion/Exclusion criteria will apply. |
Criterios Clave de Exclusión de la Parte A: - Historial o resultado positivo de la prueba de detección del virus de la inmunodeficiencia humana (VIH). El requisito de realizar pruebas en la selección puede omitirse si no está permitido por la regulación local. - Infección actual por hepatitis C (definida como anticuerpos positivos contra el virus de la hepatitis C (VHC) y ARN del VHC detectable). Los participantes con anticuerpos contra el VHC positivos y ácido ribonucleico (ARN) del VHC indetectable son elegibles para participar en el estudio (Centros para el Control y la Prevención de Enfermedades de los Estados Unidos). - Infección actual por hepatitis B (definida como positiva para el antígeno de superficie de la hepatitis B (HBsAg) y / o el anticuerpo anti-Hepatitis B Core (HBc)). Participantes con inmunidad a la hepatitis B por una infección natural previa (definida como HBsAg negativo, anti-HBc positivo y anticuerpo de superficie antihepatitis B (HBs) positivo o vacunación (definida como HBsAg negativo, anti-HBc negativo y anti-HBs positivo) son elegibles para participar en el estudio. - Antecedentes de reacción de hipersensibilidad sistémica al tofersen, a los excipientes contenidos en la formulación y, en su caso, a cualquier agente de diagnóstico que deba administrarse durante el estudio. - Historia de trastorno neuromuscular o neurológico de confusión que se espera que tenga un curso progresivo (es decir, empeoramiento) durante el estudio, y / o se espera que esté asociado con elevaciones en la NF, en opinión del investigador. - Presencia de riesgo de hemorragia aumentada o incontrolada y / o riesgo de hemorragia que, si no se maneja de manera óptima, podría colocar a un participante en un mayor riesgo de hemorragia intraoperatoria o posoperatoria. - Deterioro cognitivo significativo, demencia clínica o enfermedad psiquiátrica inestable, incluida psicosis, ideación suicida, intento de suicidio o depresión mayor no tratada ≤ 90 días de selección, que en opinión del investigador interferiría con los procedimientos del estudio. - Necesidad anticipada, en opinión del investigador, de la administración de cualquier medicamento antiplaquetario o anticoagulante (p. Ej., Clopidogrel) que no se puede continuar o mantener de forma segura para un procedimiento de LP, si es necesario, de acuerdo con las pautas locales o institucionales y / o la determinación del investigador . - Tratamiento con otro medicamento en investigación (incluidos medicamentos en investigación para ELA a través de programas de uso compasivo), agente biológico o dispositivo dentro de 1 mes o 5 vidas medias del agente del estudio, lo que sea más largo. Específicamente, no se permite ningún tratamiento previo con micro ARN interferentes, terapia con células madre o terapia génica. - Inscripción actual o plan para inscribirse en cualquier estudio clínico intervencionista en el que se haya aprobado un tratamiento, agente biológico, dispositivo o terapia en investigación para uso en investigación. La participación en un estudio no intervencionista centrado en la historia natural de la ELA puede permitirse a discreción del investigador.
NOTA: Se aplicarán otros criterios de inclusión / exclusión definidos por el protocolo. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Parts B and C: Percentage of Participants with Emergence of Clinically Manifested ALS Within 12 Months of Part B Baseline |
Partes B y C: Porcentaje de participantes con aparición de ELA clínicamente manifestada dentro de los 12 meses posteriores al inicio de la Parte B |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1. Parts B and C: Percentage of Participants with Emergence of Clinically Manifested ALS Within 2 Years of Part B Baseline 2. Parts B and C: Time to Emergence of Clinically Manifested ALS 3. Parts B and C: Change in Revised ALS Functional Rating Scale (ALSFRS-R) Total Score 4. Parts B and C: Change from Baseline in Percent Predicted Slow Vital Capacity (SVC) 5. Parts B and C: Percentage of Participants with Ventilation Assistance-free Survival (VAFS) 6. Parts B and C: Percentage of Participants with Overall Survival 7. Parts B, C and D: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) during the Treatment Period 8. Parts B, C and D: Change from Baseline in Plasma NfL Concentrations 9. Parts B, C and D: Change in Total Cerebrospinal Fluid (CFL) SOD1 Concentrations |
1. Partes B y C: Porcentaje de participantes con aparición de ELA clínicamente manifestada dentro de 2 años al inicio de la parte B 2. Partes B y C: tiempo de aparición de la ELA clínicamente manifestada 3. Partes B y C: Cambio en la puntuación total de la Escala de calificación funcional revisada de ALS (ALSFRS-R) 4. Partes B y C: cambio con respecto al valor inicial en el porcentaje de capacidad vital lenta prevista (CVS) 5. Partes B y C: Porcentaje de participantes con supervivencia sin asistencia de ventilación (VAFS) 6. Partes B y C: porcentaje de participantes con supervivencia general 7. Partes B, C y D: número de participantes con eventos adversos (EA) y eventos adversos graves (AAG) durante el período de tratamiento 8. Partes B, C y D: cambio con respecto al valor inicial en las concentraciones plasmáticas de NfL 9. Partes B, C y D: cambio en las concentraciones totales de líquido cefalorraquídeo (CFL) SOD1 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Part B, C and D: Up to 2 years |
Parte B, C y D: hasta 2 años |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Part A: Natural History Run-in: blood draws approx. every 28 days to access NfL levels |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Brazil |
Canada |
Japan |
Korea, Republic of |
Russian Federation |
United States |
Belgium |
Bulgaria |
France |
Germany |
Italy |
Poland |
Spain |
Sweden |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is last protocol-specified contact with the last participant. |
El final del estudio es el último contacto especificado por el protocolo con el último participante |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |